Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study

Table 1 Relationship between β1 integrin expression with clinicopathologic features and classical immunohistochemical markers in breast cancer, including VEGF

Clinicopathologic Features and Immunohistochemical Markers		β1 Integrin^-		β1 Integrin⁺		P-value
		n (151)	(%)	n (74)	(%)
Age (years)	<50	65	43.0	27	36.5	0.213^a
Age (years)	>50	86	67.0	47	63.5
Menstrual Status	Pre-menopausal	54	35.8	24	32.4	0.367^a
Menstrual Status	Post-menopausal	97	64.2	50	67.6
Size (mm)	<20	49	32.5	19	25.7	0.442^b
	20-50	55	36.4	33	44.6
	>50	47	31.1	22	29.7
Tumoral Grade	I	57	37.7	25	33.8	0.845^b
	II	71	47.0	37	50.0
	III	23	15.2	12	16.2
Lymph node Status	Negative	75	49.7	33	44.6	0.283^a
Lymph node Status	Positive	76	50.3	41	55.4
Clinical Stage	I	22	14.6	10	13.5	0.677^b
	II	72	47.7	30	40.5
	III	49	32.5	30	40.5
	IV	8	5.3	4	5.4
Death	No	116	76.8	40	54.1	0.001 ^a
Death	Yes	35	23.2	34	45.9
Metastasis	No	115	76.2	48	64.9	0.05 ^a
Metastasis	Yes	36	23.8	26	35.1
ER	Negative	48	31.8	21	28.4	0.359^a
ER	Positive	103	68.2	53	71.6
PR	Negative	64	42.4	33	44.6	0.431^a
PR	Positive	87	57.6	41	55.4
p53	Negative	114	75.5	51	68.9	0.187^a
p53	Positive	37	24.5	23	31.1
Ki-67	Negative	107	70.9	54	73.0	0.435^a
Ki-67	Positive	44	29.1	20	27.0
HER2	Negative	126	83.4	52	70.3	0.019 ^a
HER2	Positive	25	16.6	22	29.7
VEGF	Negative	114	75.5	66	89.2	0.011 ^a
	Positive	37	24.5	8	10.8